Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
T-DXd plus ramucirumab in HER2-low gastric or gastroesophageal junction adenocarcinoma
KCT0008627Phase 2Recruiting
- Sponsor
- AstraZeneca
- Start
- Feb 2024
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of trastuzumab deruxtecan, ramucirumab in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by AstraZeneca. Started Feb 2024; status: recruiting.
02
Drugs
trastuzumab deruxtecanramucirumab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on KCT0008627.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0008627.